BEUDAMED
    FDA Adverse Event Injury Summary report: N

    CAPIOX RX OXYGENATOR

    MDR report key: 19879304 · Received July 31, 2024

    Report

    Report Number
    9681834-2024-00134
    Event Type
    Injury
    Date Received
    July 31, 2024
    Date of Event
    July 4, 2024
    Report Date
    July 31, 2024
    Manufacturer
    TERUMO CORPORATION, ASHITAKA
    Product Code
    DTZ
    UDI-DI
    04987350763471
    PMA / PMN Number
    K022115
    Adverse Event
    Yes
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    BG
    Reporter Occupation
    OTHER
    Health Professional
    N

    Narratives

    Additional Manufacturer Narrative · 0

    A1: PATIENT IDENTIFIER: REQUESTED, NOT PROVIDED. A2: AGE OR DATE OF BIRTH: 2Y 2MONTH. A3A: SEX: REQUESTED, NOT PROVIDED. A3B: GENDER: N/A. A4: WEIGHT: 9.6 A5: ETHNICITY: REQUESTED, NOT PROVIDED. A6: RACE: REQUESTED, NOT PROVIDED. D6A: IMPLANTED DATE: DEVICE WAS NOT IMPLANTED. D6B: EXPLANTED DATE: DEVICE WAS NOT EXPLANTED. E2: HEALTH PROFESSIONAL: REQUESTED, UNKNOWN. E3: OCCUPATION: REQUESTED, UNKNOWN. G4: 510K: K022115, K130493. THE ACTUAL SAMPLE HAS NOT BEEN RECEIVED YET. NO ANOMALY WAS FOUND IN THE MANUFACTURING RECORD AND SHIPPING INSPECTION RECORDS OF THE ACTUAL PRODUCT. NO OTHER SIMILAR REPORT OF THE PRODUCT WITH THE PRODUCT CODE/LOT# INVOLVED WAS FOUND. THE INVESTIGATION IS CURRENTLY ONGOING. ONCE THE INVESTIGATION IS COMPLETE, A FOLLOW-UP REPORT WILL BE SUBMITTED. TERUMO MEDICAL PRODUCTS (TMP) (IMPORTER) REGISTRATION NO. 2243441 IS SUBMITTING THIS REPORT ON BEHALF OF ASHITAKA FACTORY OF TERUMO CORPORATION (MANUFACTURER) REGISTRATION NO. 9681834.

    Additional Manufacturer Narrative · 0

    THIS REPORT IS SENT AS FOLLOW-UP NO. 1 TO CORRECT SECTIONS D4 AND H4, UPDATE SECTIONS D9 AND H3, AND PROVIDE THE COMPLETE INVESTIGATION RESULTS. THE ACTUAL DEVICE HAS BEEN RETURNED FOR EVALUATION. FROM THE SERIAL NUMBER OF THE ACTUAL SAMPLE, IT WAS FOUND THAT THE LOT NUMBER WAS 230703 INSTEAD OF THE NUMBER PROVIDED IN THE INITIAL REPORT. AN INVESTIGATION OF THE ACTUAL SAMPLE WAS CONDUCTED. UPON RECEIPT, A VISUAL INSPECTION OF THE SAMPLE REVEALED NO ANOMALIES SUCH AS BREAKAGE. AFTER RINSING AND DRYING THE SAMPLE, THE OXYGEN TRANSFER AND CARBON DIOXIDE REMOVAL RATES WERE MEASURED ACCORDING TO THE PRODUCT INSPECTION PROCEDURE. THE RESULTS CONFIRMED THAT THE SAMPLE MET THE FACTORY'S SPECIFICATIONS, WITH NO ANOMALIES DETECTED. BOVINE BLOOD CONDITIONS: HB: 12G/DL, TEMP.: 37°C, PH: 7.4, SVO2: 65%, PVCO2: 45MMHG, CIRCULATION CONDITIONS: BLOOD FLOW RATE: 2L/MIN AND 1L/MIN, V/Q: 1, FIO2: 100%, O2 TRANSFER VOLUME: @2L/MIN: 123ML/MIN, @1L/MIN: 69ML/MIN, CO2 REMOVAL VOLUME: @2L/MIN: 103ML/MIN, @1L/MIN: 59ML/MIN. A REVIEW OF THE MANUFACTURING AND SHIPPING INSPECTION RECORDS FOR THE SAMPLE WAS CONDUCTED. NO ANOMALIES WERE FOUND IN THE PAST COMPLAINT FILES, AND NO OTHER SIMILAR REPORTS INVOLVING THE PRODUCT CODE/LOT NUMBER WERE IDENTIFIED. BASED ON THE INVESTIGATION RESULTS, THE GAS TRANSFER PERFORMANCE OF THE ACTUAL SAMPLE AFTER RINSING MET THE FACTORY'S SPECIFICATIONS, AND NO ANOMALIES WERE FOUND IN THE MANUFACTURING RECORDS. SINCE NO ANOMALIES WERE FOUND IN THE ACTUAL SAMPLE, IT WAS NOT POSSIBLE TO DETERMINE THE CAUSE OF THE OCCURRENCE. RELEVANT INSTRUCTIONS FOR USE (IFU) REFERENCE: START GAS SUPPLY WITH V/Q=1, AND FIO2=100%, THEN MAKE ADJUSTMENTS BASED ON BLOOD GAS MEASUREMENTS. MEASURE BLOOD GASES AND MAKE NECESSARY ADJUSTMENTS AS FOLLOWS. A. CONTROL PAO2 BY CHANGING CONCENTRATION OF OXYGEN IN VENTILATING GAS USING GAS BLENDER. TO DECREASE PAO2, DECREASE FIO2. TO INCREASE PAO2, INCREASE FIO2. B. CONTROL PACO2 BY CHANGING THE TOTAL GAS FLOW. TO DECREASE PACO2, INCREASE TOTAL GAS FLOW. TO INCREASE PACO2, DECREASE TOTAL GAS FLOW. UPON PATIENT REWARMING, ADJUST O2 CONCENTRATION, GAS FLOW RATE AND BLOOD FLOW RATE BY INCREASING THEM AS NEEDED BASED ON AN INCREASE IN PATIENTS' METABOLISM. FAILURE TO ADJUST THE GAS SUPPLY AND THE BLOOD FLOW RATE APPROPRIATELY MAY CAUSE INSUFFICIENT O2 SUPPLY NEEDED OR THE AMOUNT OF THE PATIENT'S GASEOUS METABOLISM. A PHENOMENON CALLED WET LUNG MAY OCCUR WHEN WATER CONDENSATION OCCURS INSIDE FIBERS OF MICROPOROUS MEMBRANE OXYGENATORS WITH BLOOD FLOWING EXTERIOR TO THE FIBERS. THIS MAY OCCUR WHEN OXYGENATORS ARE USED FOR A LONGER PERIOD OF TIME. IF WATER CONDENSATION AND/OR A DECREASE IN PAO2 AND/OR AN INCREASE IN PACO2 IS NOTED DURING EXTENDED OXYGENATOR USE, BRIEFLY INCREASING THE GAS FLOW RATE MAY IMPROVE THE PERFORMANCE. INCREASE GAS FLOW RATE, TO 5 L/MIN FOR 10 SECONDS. DO NOT REPEAT THIS FLUSHING TECHNIQUE, EVEN IF OXYGENATOR PERFORMANCE IS NOT IMPROVED.

    Description of Event or Problem · 0

    THE USER FACILITY REPORTED THAT DURING SURGERY, FIRST STAGE OXYGENATION DID NOT WORK IN THIS OXYGENATOR. AT THE SAME TIME, THE USER CHANGES THE OXYGENATOR PART ONLY AND THE RESERVOIR REMAINS THE SAME. AFTER THAT, THE OXYGENATION WORKS, AND THE SURGERY CONTINUES. GAS LINE/SUPPLY ARE OKAY. FIO2 IS ALSO SUFFICIENT. THE EVENT OCCURRED INTRA-OPERATIVELY. THE PATIENT'S FINAL IMPACT WAS NOT HARMED. NO PATIENT'S HARM WAS CAUSED BY THIS INCIDENT, BUT THE PRODUCT WAS REPLACED.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1979556 CAPIOX RX OXYGENATOR OXYGENATOR, CARDIOPULMONARY BYPASS DTZ TERUMO CORPORATION, ASHITAKA N/A 230703 04987350763471

    Patients

    Seq Age Sex Outcome Treatment
    1 24 MO Female Required Intervention